【摘要】 目的评价中药联合α-干扰素对慢性乙型肝炎患者血清HBsAg的影响。方法按照系统评价的原则制定检索策略,收集符合纳入标准的研究并采集相关信息和Meta分析。结果20篇文献符合纳入标准,10个联合治疗方案、1 921名患者纳入研究,苦参素联合α-干扰素治疗慢性乙型肝炎疗程为3个月,6个月时相对危险度分别为RR1.71,1.83;95%可信区间CI(0.82,3.56),(0.92,3.65),联合组与对照组相比无统计学意义。其他联合方案与对照组相比均无统计学意义。结论就现有的研究来看,还不能得出中药联合α-干扰素治疗慢性乙型肝炎对血清HBsAg转阴率优于单用α-干扰素的结论。更多还原

【Abstract】 Objective To study the influence of Chinese Patent Medicines combined with α-interferon on HBsAg chronic hepatits B patients.MethodsSearch strategy was formulated according to the Cochrane systematic review,related information of the literatures met inclusion criteria was gathered.Results20 trials met the inclusion criteria,10 sorts of Chinese Patent Medicines,10 sorts of treatment prescription,1921 patients were included.No significant statistic difference between the two groups was identified after treatment.ConclusionAccording to existing literatures,we could not reach a conclusion that the therapeutic effect of Chinese Patent Medicines combined with α-interferon on serum-HBsAg in chronic hepatitis B patients were surpass over that of α-interferon alone.更多还原